PRO-ACT Study Compares Topical Minoxidil 5% with PRCT vs Plain Minoxidil 5% in Androgenetic Alopecia-Combination Shows Superior Efficacy
A Novel formulation of Minoxidil 5% and PRCT (Procapil, Redensyl, Caffeine, and Transcutol) has emerged superior in effectiveness, tolerability, and patient satisfaction compared to plain Minoxidil 5% in individuals with Androgenetic alopecia (AGA), reveals an Indian real-world evidence study. The findings come from the PRO-ACT study, published in the September 2025 issue of theIP Indian Journal of Clinical and Experimental Dermatology. Androgenetic alopecia (AGA), characterized by progressive hair follicle miniaturization, presents in distinct patterns in men and women, leading to male pattern hair loss (MPHL) and female pattern hair loss (FPHL), and affects 60–70% of the global population. Topical minoxidil remains the mainstay therapy for AGA, promoting hair regrowth by prolonging the anagen (growth) phase of hair follicles. A unique formulation of Minoxidil 5% combined with bioactive peptides such as Procapil, Redensyl, Caffeine, and Transcutol (PRCT) has been introduced to enhance effectiveness by targeting multiple pathways involved in hair growth and follicular health. Procapil boosts scalp microcirculation and counters DHT, Redensyl activates follicle stem cells, Caffeine improves blood flow and prolongs the anagen phase, while Transcutol enhances skin penetration for better efficacy. To evaluate the potential of combining minoxidil with bioactive peptides for enhanced hair regrowth in AGA, an open-label, prospective, multicenter real-world evidence (RWE) study was conducted to compare the safety and effectiveness of Minoxidil PRCT with plain 5% minoxidil solution. A total of 400 patients aged (≥18 years) with clinically diagnosed AGA and no recent history of other hair loss treatments were enrolled across 14 centers in India and treated for 4 months with either Minoxidil 5% with PRCT (n=200) or plain Minoxidil 5% (n=200). Primary outcomes, including changes in hair diameter and terminal and vellus hair counts, were assessed using trichoscopy, while secondary outcomes included patient satisfaction, compliance, and adverse events. Evaluations were conducted at baseline, at the first follow-up (2 months), and at the final follow-up (4 months). The results revealed findings which include: 1.Primary outcomes: Trichoscopic assessments 2.Secondary outcomes Fig. 1 – Patient satisfaction and Drug tolerability at the end of the study Minoxidil PRCT showed greater efficacy in improving hair density and hair diameter in the management of Androgenetic Alopecia (AGA). The novel formulation is found to be safe and well tolerated. These findings emphasize the potential benefits of combining topical Minoxidil 5% with bioactive peptides. The Minoxidil 5% with PRCT combination helps address the limitations associated with conventional plain minoxidil 5% treatment.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!